ONLINE TABLE 1: Characteristics of trials as reported in published journal articles. Values are numbers with percentages unless otherwise specified. IQR, inter quartile range

^{*} New England Journal of Medicine, Lancet, Journal of the American Medical Association, British Medical Journal, Annals of Internal Medicine, Circulation, Journal of Clinical Oncology, Blood, American Journal of Respiratory and Critical Care Medicine, Paediatrics, Annals of Neurology, Annals of Surgery

Characteristics	Subgroup analyses		
	269 publications	246 publications	AII N=515
	did not report	reported	
Sample size			
Median (IQR)	176 (68, 452)	572 (245, 1253)	347 (106, 800)
Centre status			
Multi centre	217 (80.7)	229 (93.1)	446 (86.6)
Single centre	44 (16.4)	12 (4.9)	56 (10.9)
Unclear	8 (3.0)	5 (2.0)	13 (2.5)
Study design			
Parallel	250 (92.9)	232 (94.3)	483 (93.6)
Cross-over	16 (5.9)	7 (2.8)	23 (4.5)
Factorial	2 (0.7)	6 (2.4)	8 (1.6)
Other	1 (0.4)	1 (0.4)	2 (0.4)
Study intention			
Superiority	192 (71.4)	197 (80.1)	389 (75.5)
Non-inferiority	44 (16.4)	40 (16.3)	84 (16.3)
Unclear	33 (12.3)	9 (3.7)	42 (8.2)
Unit of randomization			
Individuals	262 (97.4)	245 (99.6)	507 (98.4)
Clusters	6 (2.2)	1 (0.4)	7 (1.4)
Body parts	1 (0.4)	0 (0)	1 (0.2)
Sponsorship [†]			
Non-industry	99 (36.8)	86 (35.0)	185 (35.9)
Industry	170 (63.2)	160 (65.0)	330 (64.1)
High impact journal *			
Yes	52 (19.3)	115 (46.7)	167 (32.4)
No	217 (80.7)	131 (53.3)	348 (67.6)
Clinical field			
Oncology	41 (15.2)	52 (21.1)	93 (18.2)
	1		

⁺ Categorization was based on information from protocol – same as in TABLE 1.

Cardiovascular	24 (8.9)	51 (20.7)	75 (14.6)
Infectious disease	18 (6.7)	19 (7.7)	37 (7.2)
Neurology	17 (6.3)	18 (7.3)	35 (6.8)
Endocrinology	18 (6.7)	11 (4.5)	29 (5.6)
Other	151 (56.1)	95 (38.6)	246 (47.8)
Results of primary endpoint			
statistically significant			
Yes	127 (47.2)	122 (49.6)	249 (48.3)
No	101 (37.5)	116 (47.2)	217 (42.1)
No primary endpoint reported	41 (15.2)	8 (3.3)	49 (9.5)